Market Overview - The Shanghai Composite Index closed at 3870.60 points, slightly above the six-month moving average, with a change of -0.12% [1] - The total trading volume of A-shares reached 25,483.12 billion yuan [1] Stocks Breaking the Six-Month Line - A total of 50 A-shares have surpassed the six-month moving average today, with notable stocks including Shanghai Construction, Yihualu, and Runjian Shares, showing divergence rates of 9.89%, 9.08%, and 9.07% respectively [1] - Stocks with smaller divergence rates that just crossed the six-month line include Zhuhai Port, Zhongzhou Special Materials, and Nanjing Chemical Fiber [1] Top Performers - Shanghai Construction (600170) saw a price increase of 9.96% with a turnover rate of 6.20% and a divergence rate of 9.89% [1] - Yihualu (300212) increased by 10.90% with a turnover rate of 12.71% and a divergence rate of 9.08% [1] - Runjian Shares (002929) rose by 9.99% with a turnover rate of 10.76% and a divergence rate of 9.07% [1] Additional Notable Stocks - Other significant gainers include Huafu Times (600169) with a 10.08% increase and a divergence rate of 7.82%, and Shang (002042) with a 10.06% increase and a divergence rate of 7.70% [1] - The stock of Fule New Materials (605488) rose by 10.01% with a divergence rate of 6.93% [1] Stocks with Lower Divergence Rates - Stocks like Zhonghuan Hailu (301040) and Baitong Energy (001376) showed increases of 1.91% and 1.55% respectively, with divergence rates of 1.09% and 1.00% [2] - Longyuan Construction (600491) increased by 1.91% with a divergence rate of 0.97% [2]

Group 1 - The company announced that its wholly-owned subsidiary, Harbin Longjiang Animal Health Biotechnology Co., Ltd., has changed its business scope and completed the registration procedures for the change [2] - The company has obtained a new business license issued by the Administrative Approval Bureau of Harbin New Area Management Committee [2]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has announced a change in the business scope of its wholly-owned subsidiary, Harbin Longjiang Animal Health Biotechnology Co., Ltd., which has completed the necessary registration and obtained a new business license [1][2]. Group 1: Business Scope Changes - The previous business scope included veterinary drug production, veterinary drug operation, and feed additive production, along with various technical services and sales of medical devices and disinfectants [1]. - The new business scope retains the same core areas but adds the sale of pre-packaged food and wholesale of pet food and supplies [1][2]. - Other registration details of the business license remain unchanged despite the scope modification [2].

哈尔滨三联药业股份有限公司收到全资子公司哈尔滨龙江动保生物科技有 限公司的通知，其对经营范围进行了变更，并已完成工商变更登记手续，取得了 哈尔滨新区管理委员会行政审批局换发的《营业执照》。具体变更情况如下： 变更前： 经营范围：许可项目：兽药生产；兽药经营；饲料添加剂生产。一般项目： 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；农业科学研 究和试验发展；第一类医疗器械销售；第二类医疗器械租赁；第一类医疗器械生 产；非居住房地产租赁；住房租赁；消毒剂销售（不含危险化学品）；饲料原料 销售；塑料制品制造；塑料制品销售；饲料添加剂销售。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准） 变更后： 经营范围：许可项目：兽药生产；兽药经营；饲料添加剂生产。一般项目： 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；农业科学研 究和试验发展；第一类医疗器械销售；第二类医疗设备租赁；第一类医疗器械生 产；非居住房地产租赁；住房租赁；消毒剂销售（不含危险化学品）；饲料原料 销售；塑料制品制造；塑料制品销售；饲料添加剂销售；食品销售（仅销售预包 ...

Group 1 - The stock price of Har Sanlian is reported at 14.44 yuan as of August 27, 2025, down 3.80% from the previous trading day [1] - The company achieved a revenue of 413 million yuan in the first half of 2025, a year-on-year decline of 21.08%, with a net profit loss of 92.39 million yuan, reversing from profit to loss [1] - The pharmaceutical segment's revenue decreased by 24.25%, significantly impacting overall performance, while new ventures in animal health and wellness are still in the investment phase and have not yet contributed to profitability [1] Group 2 - On August 27, 2025, Har Sanlian experienced a net outflow of 38.09 million yuan in principal funds, with a cumulative net outflow of 90.42 million yuan over the past five days [2]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [2][3] Financial Performance - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08% [2] - The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [2] - For the full year of 2024, the company reported revenue of 1.132 billion yuan, down 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [4][5] Core Business Segment - The pharmaceutical segment, which is the core business, faced significant revenue pressure, generating sales of 356 million yuan in the first half of 2025, a decline of 24.25% year-on-year, accounting for 86.08% of total revenue [3][4] - Revenue from infusion products was 132 million yuan, down 12.14% year-on-year [4] - Non-infusion products saw growth in sales due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [4] New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become significant contributors to revenue and are still in the investment phase [6] - Revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [7] Subsidiary Performance - The company’s two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses [8] - Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling of raw materials, leading to a significant drop in revenue [8] - Lingbao Sanlian, in its initial phase, reported negative profit margins and increased depreciation costs after reaching operational status [8]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [1][2]. Revenue and Profit Summary - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08%. The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [1][2]. Core Business Performance - The pharmaceutical segment, which is the core business of the company, faced significant revenue pressure, resulting in a sales income of 356 million yuan, a year-on-year decline of 24.25%, accounting for 86.08% of total revenue [2][4]. - The infusion products generated sales revenue of 132 million yuan, down 12.14% year-on-year. Non-infusion products saw growth in sales volume due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [3][4]. Financial Trends - The company's 2024 annual report indicated that the pharmaceutical segment's revenue was approximately 989 million yuan, a year-on-year decrease of 13.48%, representing 87.34% of total revenue. The report highlighted the impact of centralized procurement on revenue and profit [4]. - In the first quarter of 2025, the company transitioned from profit to loss, with revenue of 205 million yuan, a year-on-year decline of 16.93%, and a net profit of -28.84 million yuan, a decrease of 253.52% [3][4]. New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become a significant revenue driver and are still in the investment phase, leading to increased operational costs without substantial revenue generation [5]. - The combined revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [5]. Subsidiary Performance - The company's two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses. Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling, while Lingbao Sanlian, in its early stages, reported negative profit margins and increased depreciation costs [6][7].

Core Points - The company, Harbin Sanlian Pharmaceutical Co., Ltd., has released its 2025 semi-annual report, which includes important financial and operational information [1][15]. - The board of directors and the supervisory board have both approved the semi-annual report and related documents, confirming that the information disclosed is true, accurate, and complete [24][26]. Group 1: Board Meeting - All directors attended the board meeting that reviewed the semi-annual report [2][11]. - The meeting was held on August 25, 2025, and all 9 directors participated in the voting process [10][12]. - The board approved the proposal regarding the 2025 semi-annual report with unanimous support [13][14]. Group 2: Supervisory Board Meeting - The supervisory board meeting was also held on August 25, 2025, with all 3 supervisors present [21][22]. - The supervisory board confirmed that the procedures for preparing and reviewing the semi-annual report complied with relevant laws and regulations [24]. - The board approved the proposal regarding the use of raised funds, stating that there were no violations or misuses of the funds [26].

哈尔滨三联药业股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：哈尔滨三联药业股份有限公司 单位：万元 | 其他关联资金往来 | 资金往来方名称 | 往来方与上 市公司的关 | 上市公司核 | 2025年期 | 2025半年度 往来累计发生 | 2025半年度 | 2025半年度 | 2025半年度 | | 往来性质（经营 性往来、非经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 算的会计科 | 初往来资 | 金额（不含利 | 往来资金的利 | 偿还累计发生 | 期末往来资金 | 往来形成原因 | | | | | 联关系 | 目 | 金余额 | 息） | 息（如有） | 金额 | 余额 | | 性往来） | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | | 兰西哈三联制药有限公司 | 控股子公司 | 其他应收款 | 107.29 | 747.58 | | - | 854.87 ...

哈尔滨三联药业股份有限公司 2025 年半年度财务报告 哈尔滨三联药业股份有限公司 2025 年半年度财务报告 （未经审计） 2025 年 8 月 1 | 一、审计报告 | 3 | | --- | --- | | 二、财务报表 | 3 | | 三、公司基本情况 20 | | | 四、财务报表的编制基础 21 | | | 五、重要会计政策及会计估计 21 | | | 六、税项 | 42 | | 七、合并财务报表项目注释 43 | | | 八、研发支出 82 | | | 九、合并范围的变更 85 | | | 十、在其他主体中的权益 88 | | | 十一、政府补助 93 | | | 十二、与金融工具相关的风险 95 | | | 十三、公允价值的披露 97 | | | 十四、关联方及关联交易 99 | | | 十五、股份支付 105 | | | 十六、承诺及或有事项 106 | | | 十七、资产负债表日后事项 106 | | | 十八、其他重要事项 107 | | | 十九、母公司财务报表主要项目注释 108 | | | 二十、补充资料 118 | | 哈尔滨三联药业股份有限公司 2025 年半年度财务报告 一、 ...